zepbound tirzepatide Zepbound® with Ivím Health's Weight Management Program Eli Lilly to sell Zepbound

Bioverse Review is a telehealth GLP-1 provider platform emphasizing personalized care protocols

Treatment with semaglutide, compared to placebo, is associated with significant lower incidence of all-cause and CV mortality, as well major CV and kidney events across the continuum of cardio-kidney-metabolic syndrome

Discover how semaglutide (GLP-1) injections support safe, doctor-guided weight management.

Beginning July 1, 2026, the Medicare GLP-1 Bridge Program may allow...

We also describe the development of incretin-based pharmacotherapy, starting with exendin- 4 and ending with the identification of multi-incretin hormone receptor agonists, which appear to be the next major step in the fight against T2DM and obesity

French researchers have developed a new drug delivery system that could cut the dosing schedule for type 2 diabetes and weight control drug semaglutide to just once a month, according researchpresented at this year's annual meeting of the European Association for the Study of Diabetes (EASD)."Glucagon-like peptide-1 agonist (GLP-1) drugs have transformed type 2 diabetes care, but weekly injections can be burdensome for patients, said lead author, Dr Claire Mgret from Adocia, Lyon, France, the